Cargando…

298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population

BACKGROUND: The hepatitis C virus (HCV) epidemic in the United States disproportionately impacts people who inject drugs (PWID) who account for 80% of new infections and have a high prevalence of chronic infection. Baltimore City has the highest case rate of HCV in the state of Maryland with over 25...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayanan, Shivakumar, Abutaleb, Ameer, Hoffmann, Jennifer, Greenblatt, Aaron, Kottilil, Shyam, D’Amore, Aaron, Brokus, Christopher, Kattakuzhy, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811326/
http://dx.doi.org/10.1093/ofid/ofz360.373
_version_ 1783462457840238592
author Narayanan, Shivakumar
Abutaleb, Ameer
Hoffmann, Jennifer
Greenblatt, Aaron
Kottilil, Shyam
D’Amore, Aaron
Brokus, Christopher
Kattakuzhy, Sarah
author_facet Narayanan, Shivakumar
Abutaleb, Ameer
Hoffmann, Jennifer
Greenblatt, Aaron
Kottilil, Shyam
D’Amore, Aaron
Brokus, Christopher
Kattakuzhy, Sarah
author_sort Narayanan, Shivakumar
collection PubMed
description BACKGROUND: The hepatitis C virus (HCV) epidemic in the United States disproportionately impacts people who inject drugs (PWID) who account for 80% of new infections and have a high prevalence of chronic infection. Baltimore City has the highest case rate of HCV in the state of Maryland with over 25% of new cases statewide occurring in the city. Only 10% of PWID have access to directly acting antiviral (DAA) therapy and are cured of HCV. Medication-assisted treatment (MAT) is currently offered in isolated facilities with limited access to other specialty care. In this study, we collocated HCV care continuum in a MAT facility offering opioid agonist therapy and psychosocial interventions METHODS: Collocation of HCV care was initiated in an MAT (methadone and buprenorphine) clinic, the University of Maryland Drug Treatment Center (UMDTC) serving over 700 patients, for Opioid Use Disorder (OUD) in Baltimore City (Figure 1). Screening for HCV was expanded through health education of patients and staff and expanded testing. HCV antibody-positive patients were linked to care with an experienced HCV provider or referred to hepatologists (decompensated cirrhosis). RESULTS: Most of the attendees were African-American with an average age of 52 years. 354 out of 701 clients attending clinic for methadone/suboxone (50.5%) were screened for HCV. Of the 251 patients who were hepatitis C antibody positive (70% of tested), 54 had undetectable HCV RNA. 46 had no HCV RNA labs available. 151 of the remaining HCV Ab positive patients who had a detectable HCV RNA result were evaluated for treatment (Figure 2). At initial assessment, 45 (48%) with liver fibrosis staged greater than F3, including 25 (27%) with cirrhosis. Sixty-four patients initiated DAA therapy. Fifty-four patients completed treatment (84%). Forty patients achieved sustained virologic response (100%) and 14 patients who completed treatment await SVR labs. CONCLUSION: Collocation of HCV care continuum in MAT setting is an effective way to achieve micro elimination of HCV. The follow-up of this marginalized population still remains challenging given the high rates of homelessness and incarceration. In this regard, coordinated care between MAT settings and prisons are likely to demonstrate successful elimination of hepatitis C. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811326
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68113262019-10-29 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population Narayanan, Shivakumar Abutaleb, Ameer Hoffmann, Jennifer Greenblatt, Aaron Kottilil, Shyam D’Amore, Aaron Brokus, Christopher Kattakuzhy, Sarah Open Forum Infect Dis Abstracts BACKGROUND: The hepatitis C virus (HCV) epidemic in the United States disproportionately impacts people who inject drugs (PWID) who account for 80% of new infections and have a high prevalence of chronic infection. Baltimore City has the highest case rate of HCV in the state of Maryland with over 25% of new cases statewide occurring in the city. Only 10% of PWID have access to directly acting antiviral (DAA) therapy and are cured of HCV. Medication-assisted treatment (MAT) is currently offered in isolated facilities with limited access to other specialty care. In this study, we collocated HCV care continuum in a MAT facility offering opioid agonist therapy and psychosocial interventions METHODS: Collocation of HCV care was initiated in an MAT (methadone and buprenorphine) clinic, the University of Maryland Drug Treatment Center (UMDTC) serving over 700 patients, for Opioid Use Disorder (OUD) in Baltimore City (Figure 1). Screening for HCV was expanded through health education of patients and staff and expanded testing. HCV antibody-positive patients were linked to care with an experienced HCV provider or referred to hepatologists (decompensated cirrhosis). RESULTS: Most of the attendees were African-American with an average age of 52 years. 354 out of 701 clients attending clinic for methadone/suboxone (50.5%) were screened for HCV. Of the 251 patients who were hepatitis C antibody positive (70% of tested), 54 had undetectable HCV RNA. 46 had no HCV RNA labs available. 151 of the remaining HCV Ab positive patients who had a detectable HCV RNA result were evaluated for treatment (Figure 2). At initial assessment, 45 (48%) with liver fibrosis staged greater than F3, including 25 (27%) with cirrhosis. Sixty-four patients initiated DAA therapy. Fifty-four patients completed treatment (84%). Forty patients achieved sustained virologic response (100%) and 14 patients who completed treatment await SVR labs. CONCLUSION: Collocation of HCV care continuum in MAT setting is an effective way to achieve micro elimination of HCV. The follow-up of this marginalized population still remains challenging given the high rates of homelessness and incarceration. In this regard, coordinated care between MAT settings and prisons are likely to demonstrate successful elimination of hepatitis C. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811326/ http://dx.doi.org/10.1093/ofid/ofz360.373 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Narayanan, Shivakumar
Abutaleb, Ameer
Hoffmann, Jennifer
Greenblatt, Aaron
Kottilil, Shyam
D’Amore, Aaron
Brokus, Christopher
Kattakuzhy, Sarah
298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title_full 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title_fullStr 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title_full_unstemmed 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title_short 298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population
title_sort 298. collocation of hepatitis c care continuum with mat for high-prevalence, high-risk population
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811326/
http://dx.doi.org/10.1093/ofid/ofz360.373
work_keys_str_mv AT narayananshivakumar 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT abutalebameer 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT hoffmannjennifer 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT greenblattaaron 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT kottililshyam 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT damoreaaron 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT brokuschristopher 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation
AT kattakuzhysarah 298collocationofhepatitisccarecontinuumwithmatforhighprevalencehighriskpopulation